NextCure (NXTC) to Release Earnings on Thursday

NextCure (NASDAQ:NXTC) will likely be posting its Q1 2026 results before the market opens on Thursday, April 30th. Analysts expect NextCure to post earnings of ($1.85) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 4, 2026 at 4:00 PM ET.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $1.45. On average, analysts expect NextCure to post $-8 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

NextCure Price Performance

Shares of NXTC stock opened at $12.00 on Thursday. The firm has a fifty day moving average of $11.90 and a two-hundred day moving average of $11.47. The firm has a market cap of $42.72 million, a P/E ratio of -0.60 and a beta of 1.57. NextCure has a 1-year low of $4.09 and a 1-year high of $15.74.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of NextCure in a report on Wednesday, January 28th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Hedge Funds Weigh In On NextCure

Several institutional investors have recently made changes to their positions in NXTC. Exome Asset Management LLC bought a new stake in shares of NextCure in the 4th quarter worth approximately $2,341,000. AWM Investment Company Inc. bought a new position in NextCure during the 4th quarter worth $1,665,000. Ikarian Capital LLC acquired a new stake in NextCure in the fourth quarter worth $3,382,000. Affinity Asset Advisors LLC increased its position in NextCure by 28.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock worth $3,509,000 after buying an additional 55,412 shares during the period. Finally, Squadron Capital Management LLC bought a new stake in NextCure in the fourth quarter valued at $3,363,000. 42.65% of the stock is owned by institutional investors.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.